Research trends and highlights in PD-1/PD-L1 inhibitor immunotherapy in lung cancer: a bibliometric analysis
Bibliometric analysis indicates that PD-1/PD-L1 inhibitors are pivotal in lung cancer immunotherapy. Research in this domain focuses on identifying biomarkers within the tumor microenvironment, addressing immune evasion and resistance to maximize efficacy, and mitigating adverse effects.
Authors
- Fei Wu
- Zheng Gu (ORCID: https://orcid.org/0009-0009-6953-1604)
- Jing Ai (ORCID: https://orcid.org/0000-0003-3717-981X)
- Junxian Yu (ORCID: https://orcid.org/0000-0002-2087-5467)
- Qiang Su (ORCID: https://orcid.org/0000-0003-3230-2882)
- Erle Deng
Institutions
- Capital Medical University (CN)
- Chinese Center For Disease Control and Prevention (CN)
- Beijing Friendship Hospital (CN)
Publication Details
- Journal
- Discover Oncology
- Published
- 2025-03-11
- DOI
- https://doi.org/10.1007/s12672-025-02052-x
- Citations
- 3
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 3.14